Skip to main content
Beyfortus® logo

How to Order


Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection is available as pre-filled syringes with dosing options based on the patient's weight and age. If you need help ordering, request or contact a Sanofi representative for assistance.1

Ordering

Respiratory syncytial virus (RSV) season is unpredictable2,3

Make sure your practice is prepared

Beyfortus is available through VaccineShop,* VaxServe, and select wholesalers and distributors. Simply create an account or log in to your existing account to order Beyfortus with immediate shipping.

VaccineShop Sanofi logo

Visit VaccineShop

Sanofi’s healthcare professional destination for vaccines, medical supplies, patient resources, and practice support.

VaxServe logo

Visit VaxServe

A trusted vaccine distributor offering customized ordering, business tools, educational resources, and personalized support.

*All direct customers on VaccineShop will receive 60-day billing terms—excludes wholesale, distributor, and public orders. 
Beyfortus 50 mg and 100 mg Injection is available to purchase through wholesalers and distributors. Please call 1-800-VACCINE for more information.

A single dose for the vast majority of infants based on body weight (5O mg intramuscular [IM] dose if <5 kg, 100 mg IM dose if ≥5 kg)1

For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose is recommended as soon as the child is stable after surgery. Please consult the Prescribing Information for complete information on dosing in this circumstance. Second season: children up to 24 months of age, regardless of body weight, who remain at increased risk for severe RSV, the recommended dosage of Beyfortus is a single 200 mg dose administered as 2 IM injections (2 x 100 mg).

Each Beyfortus pre-filled syringe is for one-time use only1

Shipping1

Beyfortus is a sterile, preservative-free injection solution that appears clear to opalescent and colorless to yellow.

Packaging and delivery type

Pre-filled syringe

Beyfortus is an IM injection administered through a pre-filled syringe by a healthcare provider.

5-pack cartons

Each carton of Beyfortus contains 5 pre-filled syringes for one-time use.

Dose strengths and formulation

First RSV season

<5 kg weight
50 mg/0.5 mL

NDC: 49281-575-15

First RSV season

≥5 kg weight
100 mg/1 mL

NDC: 49281-574-15

Second RSV season*

Any weight
2 x 100 mg/1 mL

NDC: 49281-574-15

*For children who remain vulnerable to severe RSV disease up to 24 months of age, regardless of weight.1

Babies 1

The resources you need to be properly reimbursed for administering Beyfortus

Frequently asked questions

Beyfortus orders are shipped immediately after ordering. Actual delivery time is not explicitly specified, but is expected to be rapid (typically within a few days, depending on distributor and location).

Order ahead of need, rather than relying on just-in-time delivery during the RSV season.
  

If you need help ordering Beyfortus: 
Primary route: Call 1-800-VACCINE for ordering and logistics support.

Additional support: Request a Sanofi rep for hands-on assistance.

Call 1-855-BEYFORTUS for general product help.

Multiple support channels are available, but 1-800-VACCINE is the key contact for ordering-related questions. 
  

Administration details for Beyfortus

Codes and reimbursement information

Important Safety Information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions
  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important Safety Information

Indication

NDC, National Drug Code.

References: 1. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. 2. Arriola CS, Kim L, Langley G, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9(5):587-595. 3. RSV in infants and young children. Centers for Disease Control and Prevention. Updated February 20, 2026. Accessed June 1, 2026. https://www.cdc.gov/rsv/infants-young-children/index.html

MAT-US-2310578-v14.0-06/2026